British Virgin Islands
Juvenescence Limited is a biotech company focussed on therapies to increase healthy human longevity. It was founded in 2017 by Jim Mellon, Dr. Greg Bailey, Dr. Declan Doogan, Anthony Chow, and Alexander Pickett. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences. Juvenescence will create or invest in new companies with ageing or age-related therapeutics, by in-license compounds from academia or industry, or doing a joint venture to develop therapeutics for longevity.
Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of ageing and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of ageing.
Chairman: Jim Mellon
26 articles with Juvenescence
Several biotech companies backed by billions are working on different approaches to developing the next big anti-aging therapy - from blood experiments to cell reprogramming.
Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, announced that Dr. Grazia Piizzi, PhD, has joined its Executive Management Team as Chief Scientific Officer.
Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, announced a partnership with Evgen Pharma plc to license its sulforaphane stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division.
Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, is pleased to announce the appointment of Dr. Ellen Donnelly to its Senior Leadership Team.
G3 Therapeutics and Juvenescence Limited Announce the Formation of Juvenomics, a Visionary Company Founded on Applying Deep Molecular Profiling and Deep Learning to Tackle Aging
Juvenescence Limited, a life sciences company focused on therapies to modify aging and increasing healthy human longevity, and G3 Therapeutics, a trailblazer biotechnology company leveraging biological big data for drug discovery and development, announced the formation of Juvenomics Limited, a joint venture between the two parent companies.
Juvenescence Limited, a life sciences company focused on modifying aging and increasing human longevity, is pleased to announce the appointment of Dr. Jean-Christophe Renondin to its Main Board of Directors, and of Dr. David Roblin and Dr. Steve Felstead to its Senior Leadership Team.
LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology
Funds will support a Phase 2a clinical trial for patients with end stage liver disease in 2020
Juvenescence Closes $100 Million Series B Round, Plans Follow on and Incremental Investments in Longevity Drug Development
Juvenescence is pleased to announce the successful closure of its $100 million Series B round, including a total of $10 million from its founders and a further $10 million each from four cornerstone investors, including Grok Ventures, the investment company of Mike Cannon-Brookes, and Michael Spencer’s private investment company, IPGL.
Juvenescence, a life sciences company targeting the intrinsic mechanisms of aging, announces that Colin Watts has joined its Management Team as CEO of Juvenescence Life.
Juvenescence's Latest Venture, Souvien Therapeutics, Creating Innovative Medicines Addressing Neurodegenerative Diseases
Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics, creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
Juvenescence Ltd, a biopharmaceutical company focused on treating aging and age-related disease, is pleased to announce its latest equity investment in BYOMass Inc., a Massachusetts-based company focused on central control of metabolism in the context of aging and age-related diseases.
Grace and Blanche, who were second cousins, for a time were believed to be the oldest living mice in the world prior to their death.
New venture expands on collaborations between Juvenescence and The Buck
Juvenescence Ltd, a biopharmaceutical company focused on modifying ageing and age-related disease, is pleased to announce the close of the first tranche of its Series B financing, in the amount of $46 million
NetraMark Corp. and Juvenescence Ltd. launch joint venture, using artificial intelligence to fight aging-related conditions
NetraMark Corp. and Juvenescence Ltd. have partnered to form NetraPharma, a joint venture that is using artificial intelligence technologies to develop therapies that could slow, halt or potentially reverse aging.
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
Proceeds provide sufficient capital to fund BioTime through major milestones for current programs, including Renevia® and OpRegen® key data and decisions
Scientists call it the "linchpin of energy metabolism".
Sensyne Health, a London-based healthcare artificial intelligence (AI) company founded by biotech entrepreneur Paul Drayson, recently launched an initial public offering (IPO) on the London AIM market. Drayson’s plan is to raise $78 million. It’s just one of many companies that are exploiting adv...
Buck Institute, Insilico Med and Juvenescence Found Napa Therapeutics to Focus on Age-Related Dis...
8/16/2018Yet another company is launched to focus on longevity and diseases of aging. The Buck Institute for Research on Aging, Insilico Medicine, an artificial intelligence (AI) company with offices and resources in the U.S., Belgium, Russia, the UK, Taiwan and Korea, and Juvenescence, also a human longe...